Literature DB >> 30546591

Transcatheter closure of ruptured sinus of Valsalva aneurysm in a pregnant woman.

Gaurav Agrawal1, Manoj Agarwal1, Kavitha Chintala1.   

Abstract

Sinus of Valsalva aneurysm (SVA) is a rare cardiac anomaly that is usually congenital, but may be acquired. They are usually asymptomatic unless they compress adjacent structures, develop thrombosis, or rupture. A ruptured SVA (RSVA) can lead to rapid hemodynamic deterioration and often needs to be addressed emergently. Surgical correction has traditionally been the treatment of choice for RSVA; however, lately they have been successfully closed percutaneously using various transcatheter devices. Few cases of RSVA during pregnancy have been reported which were conservatively or surgically managed. There is no documented case of transcatheter closure of RSVA during pregnancy. We report the first case of successful percutaneous device closure of RSVA using an Amplatzer duct occluder in a pregnant woman presenting with heart failure due to RSVA at 26 weeks of gestation. <Learning objective: Ruptured sinus of Valsalva aneurysm (RSVA) is traditionally repaired by surgery but more recently amenable to percutaneous intervention. Management of RSVA during pregnancy is complex and has been managed by surgery in the past incurring significant risk to fetus due to effects of cardiopulmonary bypass. We report a case of RSVA in pregnancy that was closed by transcatheter closure for the first time, thereby significantly reducing maternal and fetal risks. While risks are present during pregnancy, emergently indicated life-saving invasive cardiac procedures should not be denied solely on the pregnant state.>.

Entities:  

Keywords:  Percutaneous; Pregnancy; Ruptured aneurysm; Sinus of Valsalva aneurysm; Transcatheter intervention

Year:  2015        PMID: 30546591      PMCID: PMC6281898          DOI: 10.1016/j.jccase.2015.08.001

Source DB:  PubMed          Journal:  J Cardiol Cases        ISSN: 1878-5409


  16 in total

Review 1.  Cardiopulmonary bypass during pregnancy.

Authors:  A J Parry; S Westaby
Journal:  Ann Thorac Surg       Date:  1996-06       Impact factor: 4.330

2.  Patient-specific dose and radiation risk estimation in pediatric cardiac catheterization.

Authors:  Klaus Bacher; Evelien Bogaert; Régine Lapere; Daniël De Wolf; Hubert Thierens
Journal:  Circulation       Date:  2004-12-20       Impact factor: 29.690

3.  Cardiac surgery during pregnancy.

Authors:  Anish Patel; Sanjay Asopa; Augustine T M Tang; Sunil K Ohri
Journal:  Tex Heart Inst J       Date:  2008

4.  Successful outcome of a rare case of ruptured sinus of valsalva aneurysm in pregnancy.

Authors:  Vikram Talaulikar; Siddhi Verenkar; Anjali Kamat
Journal:  J Obstet Gynaecol India       Date:  2013-03-27

5.  [Ruptured sinus of Valsalva aneurysm and pregnancy: what anesthetic technique should be preferred for a scheduled cesarean section?].

Authors:  R Peláez Romero; I Grigorov; I Giménez; J L Aguilar; P Atanassoff
Journal:  Rev Esp Anestesiol Reanim       Date:  2010-03

6.  Ruptured sinus of valsalva aneurysm in a pregnant woman.

Authors:  Joshua Latzman; Amgad N Makaryus; David Rosman
Journal:  Tex Heart Inst J       Date:  2006

7.  Sinus of Valsalva aneurysms--47 years of a single center experience and systematic overview of published reports.

Authors:  Sherif Moustafa; Farouk Mookadam; Leslie Cooper; Guleid Adam; Kenton Zehr; John Stulak; David Holmes
Journal:  Am J Cardiol       Date:  2007-02-28       Impact factor: 2.778

8.  Ruptured aneurysm of right sinus of valsalva in pregnancy-a case report.

Authors:  Leena Goel; Pooja Gautam; Suchith C
Journal:  Indian J Anaesth       Date:  2009-02

9.  A meta-analysis of low-dose aspirin for the prevention of pregnancy-induced hypertensive disease.

Authors:  T F Imperiale; A S Petrulis
Journal:  JAMA       Date:  1991-07-10       Impact factor: 56.272

10.  Cardiac surgery and percutaneous intervention in pregnant women with heart disease.

Authors:  P G Pieper; E S Hoendermis; Y N Drijver
Journal:  Neth Heart J       Date:  2012-03       Impact factor: 2.380

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.